November 2005
|
Sponsored by Bimark Center
for Medical Education
|
CPE Accreditation
The Bimark Center for Medical Education (Bimark Center) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (no. 799), and complies with the Criteria for Quality for continuous pharmacy education programming. The ACPE number for this home study activity is 799-000-05-060-H01.
This program is acceptable for 1 hour (0.1 CEU) of continuing education credit in states that recognize ACPE-accredited providers. Initial release date: October 29, 2005. Program expiration date: October 29, 2006. No fees are required. For successful completion of this activity and awarding of credits, the participant must attend the entire session and achieve a score of at least 70% on the post-test. Statements of credit will be distributed via e-mail within 4 weeks of receipt of the completed post-test.
Release date: October 29, 2005; Expiration date: October 29, 2006.
Estimated time to complete: 1 hour
Lecture Components
The presentation slides, post-test, and evaluation form are available as a click through via the menu at the top of each page of this educational activity.
Target Audience
This activity is designed for pharmacists with an interest in dyslipidemia and the role of omega-3 fatty acids.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Discuss the prevalence of cardiovascular disease (CVD), focusing on dyslipidemia and the importance of targeted lipid therapy for improving cardiovascular outcomes
- Examine the emerging body of evidence on the benefits of omega-3 fatty acids within the CVD continuum
- Evaluate the differences between the available omega-3 fatty acid formulations (ie, prescription vs dietary supplements) in terms of their manufacturing process, purity standards, potency, and FDA regulation
- Identify strategies to educate patients on omega-3 fatty acids, and discuss the role of the pharmacist as part of the interdisciplinary healthcare team in implementing such strategies
Program Goal
The goal of this continuing education activity is to provide pharmacists with an overview of the role of omega-3 fatty acids in the management of dyslipidemia. This activity identifies and discusses key studies illustrating the cardiovascular benefits of omega-3 fatty acids, and explores the fundamental differences between prescription and dietary supplement formulations. Also, this activity highlights the unique position of the pharmacist in intervening and education healthcare providers and patients in improving patient outcomes.
Grant Support
Supported by an educational grant from Reliant Pharmaceuticals, Inc.
Participating Faculty
Presenter
James McKenney, PharmD
Professor Emeritus, School of Pharmacy
Virginia Commonwealth University
President/CEO, National Clinical Research, Inc.
Clinical Reviewer
Michael Miller, MD, FACC, FAHA
Associate Professor of Medicine, Epidemiology, and Preventive Medicine
Director, Center for Preventive Cardiology
Division of Cardiology
University of Maryland Medical Center
Faculty Disclosure
Dr. McKenney has received honoraria for speaking at educational programs from AstraZeneca, Kos Pharmaceuticals Inc, Merck & Co. Inc, Pfizer Inc, and Reliant Pharmaceuticals. He has served as consultant for AstraZeneca, Kos Pharmaceuticals Inc, Merck & Co. Inc, Pfizer Inc, and Sankyo Pharmaceuticals Inc. Dr. McKenney has received funding for research from AstraZeneca, GlaxoSmithKline, Kos Pharmaceuticals Inc, Merck & Co. Inc, Pfizer Inc, Schering-Plough Corporation, and Takeda Pharmaceuticals Inc.
Dr. Miller has received honoraria for speaking at educational programs from AstraZeneca, Kos Pharmaceuticals Inc, Merck & Co. Inc, Pfizer Inc, and Schering-Plough Corporation. He has served as consultant for Merck & Co. Inc, and Reliant Pharmaceuticals. Dr. Miller has received funding for research from AstraZeneca, Kos Pharmaceuticals Inc., Merck & Co. Inc, Pfizer Inc, and Schering-Plough Corporation. Dr. Miller has conducted promotional speaking events within this clinical area for AstraZeneca, Kos Pharmaceuticals Inc, Merck & Co. Inc, Pfizer Inc, and Schering-Plough Corporation.
System Requirements
This activity is accessible via Internet Explorer and Netscape browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Please direct technical questions to webmaster@princetoncme.com.
 | Slide Lecture |
